C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2

Immunology Letters

Volumn 129, Issue 1, 2010, Pages 32-38

  Toapanta, Franklin R ^a   DeAlmeida, Dilhari R ^a   Dunn, Matthew D ^a   Ross, Ted M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

C3d; CR2; DNA vaccine; Molecular adjuvant

Indexed keywords

ALANINE; ARGININE; ASPARAGINE; ASPARTIC ACID; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; DNA; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; BIOENGINEERING; CHIMERA; CONTROLLED STUDY; EMBRYO; FEMALE; GENE CONSTRUCT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BINDING SITES; CELL LINE; COMPLEMENT C3D; FEMALE; GENE DOSAGE; HIV ENVELOPE PROTEIN GP120; IMMUNITY; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, COMPLEMENT 3D; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VACCINES, DNA;

EID: 77649336866     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.12.022     Document Type: Article

References (37)

1. Weis J.J., Tedder T.F., and Fearon D.T. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A 81 (1984) 881-885
2. Iida K., Nadler L., and Nussenzweig V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 158 (1983) 1021-1033
3. Matsumoto A.K., Kopicky-Burd J., Carter R.H., Tuveson D.A., Tedder T.F., and Fearon D.T. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 173 (1991) 55-64
4. Prechl J., Baiu D.C., Horvath A., and Erdei A. Modeling the presentation of C3d-coated antigen by B lymphocytes: enhancement by CR1/2-BCR co-ligation is selective for the co-ligating antigen. Int Immunol 14 (2002) 241-247
5. Lyubchenko T., dal Porto J., Cambier J.C., and Holers V.M. Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol 174 (2005) 3264-3272
6. Koch M., Frazier J., Sodroski J., and Wyatt R. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d. Virology 340 (2005) 277-284
7. Mongini P.K., Vilensky M.A., Highet P.F., and Inman J.K. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J Immunol 159 (1997) 3782-3791
8. Rickert R.C. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr Opin Immunol 17 (2005) 237-243
9. Carroll M.C. The role of complement in B cell activation and tolerance. Adv Immunol 74 (2000) 61-88
10. Liu D., and Niu Z.X. Construction, expression and immunoassay detection of recombinant plasmid encoding fusion protein of Roman chicken complement C3d and Newcastle disease virus F gene. Scand J Immunol 68 (2008) 598-606
11. Bower J.F., Green T.D., and Ross T.M. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology 328 (2004) 292-300
12. Gor D.O., Ding X., Li Q., and Greenspan N.S. Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol Lett 102 (2006) 38-49
13. Green T.D., Montefiori D.C., and Ross T.M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77 (2003) 2046-2055
14. Green T.D., Newton B.R., Rota P.A., Xu Y., Robinson H.L., and Ross T.M. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20 (2001) 242-248
15. Mitchell J.A., Green T.D., Bright R.A., and Ross T.M. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21 (2003) 902-914
16. Ross T.M., Xu Y., Green T.D., Montefiori D.C., and Robinson H.L. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 17 (2001) 829-835
17. Toapanta F.R., and Ross T.M. Mouse strain-dependent differences in enhancement of immune responses by C3d. Vaccine 22 (2004) 1773-1781
18. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 (1996) 348-350
19. Movsesyan N., Mkrtichyan M., Petrushina I., Ross T.M., Cribbs D.H., Agadjanyan M.G., and Ghochikyan A. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol 205 (2008) 57-63
20. Wang L., Oriol Sunyer J., and Bello L.J. Immunogenicity of a bovine viral diarrhea virus E2-C3d fusion protein containing a bovine homolog of C3d. Dev Comp Immunol 29 (2005) 907-915
21. Wang L., Sunyer J.O., and Bello L.J. Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus. J Virol 78 (2004) 1616-1622
22. Test S.T., Mitsuyoshi J., Connolly C.C., and Lucas A.H. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun 69 (2001) 3031-3040
23. Barrault D.V., Steward M., Cox V.F., Smith R.A., and Knight A.M. Efficient production of complement (C3d)3 fusion proteins using the baculovirus expression vector system. J Immunol Methods 304 (2005) 158-173
24. Henson S.E., Smith D., Boackle S.A., Holers V.M., and Karp D.R. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J Immunol Methods 258 (2001) 97-109
25. Haas K.M., Toapanta F.R., Oliver J.A., Poe J.C., Weis J.H., Karp D.R., Bower J.F., Ross T.M., and Tedder T.F. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol 172 (2004) 5833-5837
26. Nagar B., Jones R.G., Diefenbach R.J., Isenman D.E., and Rini J.M. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 280 (1998) 1277-1281
27. Clemenza L., and Isenman D.E. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21). J Immunol 165 (2000) 3839-3848
28. Szakonyi G., Guthridge J.M., Li D., Young K., Holers V.M., and Chen X.S. Structure of complement receptor 2 in complex with its C3d ligand. Science 292 (2001) 1725-1728
29. Morikis D., and Lambris J.D. The electrostatic nature of C3d-complement receptor 2 association. J Immunol 172 (2004) 7537-7547
30. Bower J.F., Sanders K.L., and Ross T.M. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. Curr HIV Res 3 (2005) 191-198
31. Bower J.F., Yang X., Sodroski J., and Ross T.M. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 78 (2004) 4710-4719
32. Ross T.M., Xu Y., Bright R.A., and Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1 (2000) 127-131
33. Terrazzini N., Hannesdottir S., Delves P.J., and Lund T. DNA immunization with plasmids expressing hCGbeta-chimeras. Vaccine 22 (2004) 2146-2153
34. Watanabe I., Ross T.M., Tamura S., Ichinohe T., Ito S., Takahashi H., Sawa H., Chiba J., Kurata T., Sata T., and Hasegawa H. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine 21 (2003) 4532-4538
35. Mitsuyoshi J.K., Hu Y., and Test S.T. Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide. Infect Immun 73 (2005) 7311-7316
36. Liu F., Mboudjeka I., Shen S., Chou T.H., Wang S., Ross T.M., and Lu S. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine 22 (2004) 1764-1772
37. Wang L.X., Xu W., Guan Q.D., Chu Y.W., Wang Y., and Xiong S.D. Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization. World J Gastroenterol 10 (2004) 2072-2077